ARBUTUS BIOPHARMA CORPARBUTUS BIOPHARMA CORPARBUTUS BIOPHARMA CORP

ARBUTUS BIOPHARMA CORP

No trades
See on Supercharts

I9DN fundamentals

ARBUTUS BIOPHARMA CORP financial statements, including revenue, expenses, profit, and loss

The total revenue of I9DN for the last quarter is 1.42 M EUR, and it's 26.94% lower compared to the previous quarter. The net income of Q1 24 is -16.57 M EUR.

Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
‪0.00‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: EUR
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM
Total revenueYoY growth
Gross profitYoY growth
Pretax incomeYoY growth
Net incomeYoY growth
EBITDAYoY growth
EBITYoY growth